The Simons Foundation Autism Research Initiative (SFARI) is pleased to announce that 30 new lines of induced pluripotent stem cells (iPSC) are now available for research purposes.

Created in collaboration with the Nancy Lurie Marks Family Foundation (NLMFF), these lines were generated from peripheral blood mononuclear cells from Simons Searchlight participants with genetic variants in seven high-confidence autism risk genes, including ADNP, DYRK1A, GRIN2B, HNRNPH2, SCN2A, SETBP1 and SYNGAP. They complement the resource of existing iPSC lines for 16p11.2 duplication and deletion, PPP2R5D and CSNK2A1. Additional details about the sources of the new and existing lines and the number of donors can be found here.

Another 70 lines of iPSCs are expected to become available by spring 2022.

SFARI and NLMFF have committed to creating an additional 100 iPSC lines from Simons Searchlight participants, which will be made available in batches throughout 2022. In total, approximately 200 iPSC lines of individuals with a variety of ASD-linked neurodevelopmental conditions are planned for release by the end of 2022. To stay up-to-date on readily available iPSCs, please visit SFARI’s iPS cell models resource page regularly.

Approved researchers can order new and existing iPSCs through SFARI Base.